Wedbush Starts Alexion Pharmaceuticals (ALXN) at Neutral

September 23, 2016 6:44 AM EDT
Get Alerts ALXN Hot Sheet
Price: $126.00 --0%

Rating Summary:
    21 Buy, 9 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 12 | Down: 18 | New: 4
Trade ALXN Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.

Wedbush initiates coverage on Alexion Pharmaceuticals (NASDAQ: ALXN) with a Neutral rating and a price target of $132.00.

Analyst Heather Behanna commented, "We see Alexion as a pioneer in complement driven therapeutics. Although we expect to see continued growth in Soliris (eculizumab) sales over the next couple of years, in our view, clinical and regulatory risk surrounding pipeline expansion of eculizumab and competition on the horizon for PNH/aHUS suggests to us shares of Alexion are fairly valued at this time."

For an analyst ratings summary and ratings history on Alexion Pharmaceuticals click here. For more ratings news on Alexion Pharmaceuticals click here.

Shares of Alexion Pharmaceuticals closed at $133.69 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, New Coverage

Add Your Comment